文献速递眼底病与葡萄膜炎眼外伤

玻璃体腔注射HPMC治疗慢性结构性低眼压的前瞻性初步研究

Novel therapeutic strategies to restore vision in ocular hypotony (STRETCH): results from a prospective pilot series.
PubMed 文献 · Br J Ophthalmol · 2026-07-22

STRETCH前瞻性介入病例系列纳入8例慢性结构性低眼压(IOP<6.5 mm Hg)且存在视力潜力的患眼,每2-4周重复玻璃体腔注射HPMC(70-1400 µL),随访12个月。87.5%患眼BCVA(LogMAR)改善、IOP升高,75%患眼眼轴增加(中位1 mm)。结论认为该结构化方案可改善视力和眼球解剖结构,但需注意葡萄膜炎复发和注射后暂时性视力下降。

要点

  • 8例慢性结构性低眼压患眼接受多次玻璃体腔HPMC注射,87.5%视力(LogMAR)改善。
  • 87.5%患眼IOP升高,75%患眼眼轴增加,中位增加1 mm(范围0.6-2.9 mm)。
  • 不良事件包括2眼葡萄膜炎复发致HPMC透明度丧失及2例注射后暂时性视力下降。

核心结论

  • 玻璃体腔注射HPMC可改善慢性结构性低眼压患眼的视力并恢复眼球解剖结构,对存在视力潜力的患眼有应用前景。

研究设计与样本

  • 前瞻性介入病例系列,纳入8例慢性结构性低眼压超过3个月(IOP<6.5 mm Hg)且角膜清晰、视轴透明、有视力潜力证据的患者。
  • 患者接受多次玻璃体腔HPMC注射(70 µL-1400 µL),每2-4周一次,直至达到病前眼轴、IOP 10-15 mm Hg维持4周无低眼压征象或达到对侧眼眼轴。
  • 首次注射后随访12个月。

主要发现

  • 87.5%患眼BCVA(LogMAR)改善,1眼保持稳定;BCVA初始范围0.3-1.7 LogMAR,最终范围0.1-1.6 LogMAR。
  • 87.5%患眼IOP升高,从初始1-5 mm Hg升至3-23 mm Hg。
  • 75%患眼眼轴增加,中位增加1 mm(范围0.6-2.9 mm)。
  • 2眼出现葡萄膜炎复发致HPMC透明度丧失,经局部及玻璃体腔激素治疗处理;2例注射后暂时性视力下降,行前房穿刺后缓解。

关键数值与推荐

  • 慢性结构性低眼压定义为IOP<6.5 mm Hg且持续超过3个月。
  • 注射间隔为每2-4周,注射剂量范围70 µL-1400 µL。
  • 停药/达标条件包括达到病前眼轴、IOP 10-15 mm Hg维持4周无低眼压征象,或达到对侧眼眼轴。

临床怎么用

  • 对慢性结构性低眼压且有视力潜力的患眼,可考虑在结构化方案下重复玻璃体腔注射HPMC以改善视力和眼球解剖。
  • 治疗期间需监测葡萄膜炎复发及注射后视力下降,必要时使用激素或前房穿刺处理。

局限性

  • 本研究为小样本(8例)前瞻性病例系列,无对照组,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To report visual and anatomical outcomes following intravitreal hydroxypropylmethylcellulose (HPMC) for the treatment of chronic structural hypotony. METHODS: This study is a prospective interventional case series. Eight patients with chronic structural hypotony for more than 3 months, defined by an intraocular pressure (IOP) of <6.5 mm Hg. All patients had evidence of visual potential, clear cornea and a clear visual axis.Patients received multiple intravitreal HPMC injections (70 µL-1400 µL), administered every 2-4 weeks until either pre-morbid axial length was achieved, an IOP of 10-15 mm Hg was sustained for 4 weeks without signs of hypotony, or axial length of the contralateral eye was reached. They were followed up for 12 months after the first intravitreal injection. RESULTS: Best corrected visual acuity (BCVA) logarithm of the minimum angle of resolution (LogMAR) improved in 87.5% of eyes, with one eye remaining stable. The initial BCVA range was 0.3-1.7 LogMAR, and the final range was 0.1-1.6 LogMAR. IOP increased in 87.5% of eyes, from an initial range of 1-5 mm Hg to 3-23 mm Hg. Axial length increased in 75% of eyes, with a median increase of 1 mm (range 0.6-2.9 mm).Two adverse events occurred: uveitis flare-ups leading to loss of HPMC clarity in two eyes, managed with topical and intravitreal steroids, and two cases of temporary vision loss post-injection, resolved after paracentesis. CONCLUSION: This is the first case series to use a structured protocol for intravitreal HPMC in chronic hypotony management. The treatment improved vision and restored ocular anatomy, showing promise for managing structural hypotony in eyes with visual potential.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Orsine Murta Dias K, Yang E, Calcagni A, et al. Novel therapeutic strategies to restore vision in ocular hypotony (STRETCH): results from a prospective pilot series. Br J Ophthalmol. 2026. PMID: 41521029. doi:10.1136/bjo-2025-327866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。